Ameloss5 mg

Ameloss is a cholinesterase inhibitor used mainly for the symptomatic treatment of Alzheimer's-type dementia. It does not cure or stop the underlying progression of the disease; it helps manage cognitive symptoms.

Established / FDA-approved use

• Treatment of dementia of the Alzheimer's type, including mild, moderate, and severe stages, to improve or stabilize cognitive function and overall clinical function.

Guideline-supported / commonly used off-label

• Cognitive impairment in Parkinson's disease dementia and dementia with Lewy bodies (used off-label in some patients based on specialist judgement).
• Vascular dementia or mixed dementia, sometimes as an adjunct, though evidence is less robust than for Alzheimer's disease.

Any off-label use should only be initiated and monitored by a qualified physician (typically a neurologist or geriatrician).

Each tablet/capsule contains Donepezil Hydrochloride as the active pharmaceutical ingredient, commonly available in strengths of 5 mg and 10 mg (and in some markets 23 mg extended-release tablets), along with standard pharmaceutical excipients such as fillers, binders, and disintegrants used to formulate the tablet.

Ameloss is a piperidine-derivative, second-generation reversible acetylcholinesterase inhibitor. It is used in the management of Alzheimer's disease, a progressive neurodegenerative disorder characterized by decline in memory and cognitive function.

By slowing the breakdown of acetylcholine in the brain, Ameloss helps compensate for the loss of cholinergic neurons seen in Alzheimer's disease, thereby providing symptomatic (not curative) benefit.

Ameloss belongs to the therapeutic class of anti-dementia agents, specifically the cholinesterase inhibitors (acetylcholinesterase inhibitors), a piperidine-class compound distinct from other cholinesterase inhibitors such as rivastigmine and galantamine.

Mechanism

Donepezil Hydrochloride is a selective and reversible inhibitor of acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in the central nervous system. By inhibiting this enzyme, Donepezil Hydrochloride increases the concentration of acetylcholine available at cholinergic synapses, which is believed to improve cholinergic neurotransmission that is deficient in Alzheimer's disease.

Pharmacokinetics

• Absorption: Well absorbed orally; peak plasma concentration reached in 3-4 hours; food does not significantly affect absorption.
• Distribution: Approximately 96% bound to plasma proteins.
• Metabolism: Extensively metabolized in the liver via CYP3A4 and CYP2D6 enzymes, and also undergoes glucuronidation.
• Elimination: Long elimination half-life of approximately 70 hours, which supports once-daily dosing; excreted in both urine and feces.

Ameloss is administered orally, once daily, preferably in the evening shortly before bedtime, with or without food. Tablets should be swallowed whole with water. If a dose is missed, it should not be doubled; the next dose should be taken as scheduled, and a physician consulted if several doses are missed since re-titration may be needed.

The following interactions with Ameloss are clinically significant and well-documented:

• CYP3A4/CYP2D6 inhibitors (e.g., ketoconazole, itraconazole, quinidine, erythromycin): may increase plasma levels of Ameloss, increasing the risk of cholinergic side effects.
• CYP3A4/CYP2D6 inducers (e.g., rifampin, phenytoin, carbamazepine, chronic alcohol use): may increase the elimination of Ameloss, reducing its effectiveness.
• Anticholinergic drugs: Ameloss may interfere with the activity of anticholinergic medicines, reducing their effect.
• Cholinergic agonists and succinylcholine-type neuromuscular blockers: concurrent use with Ameloss may produce a synergistic effect, exaggerating muscle relaxation during anesthesia; anesthesia providers should be informed if a patient is taking Ameloss.
• NSAIDs: concurrent use may increase the risk of gastrointestinal bleeding, particularly in patients with a history of ulcer disease (see Precautions and Warnings).
• Beta-blockers or other drugs that reduce heart rate: additive risk of bradycardia when combined with Ameloss (see Precautions and Warnings).

The most commonly reported side effects of Ameloss include:

• Nausea and vomiting
• Diarrhea
• Insomnia and abnormal dreams
• Muscle cramps
• Fatigue
• Anorexia (decreased appetite) and weight loss
• Headache and dizziness

Less common but serious effects that require prompt medical attention include slow heart rate, fainting (syncope), signs of gastrointestinal bleeding (black or bloody stools), difficulty breathing, and seizures (see Precautions and Warnings).

Pregnancy

Alzheimer's disease dementia typically occurs in an age group beyond the reproductive years, so Ameloss is not generally indicated in pregnancy. Adequate and well-controlled human studies are lacking; animal studies have shown adverse effects (including increased stillbirths) at clinically relevant doses in late gestation. Ameloss should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; a physician must be consulted.

Lactation

It is not known whether Ameloss passes into human breast milk. Because of the potential for serious adverse effects in a nursing infant, breastfeeding is generally not recommended during treatment with Ameloss unless a physician determines it is necessary and safer alternatives are not suitable.

The following precautions apply to the use of Ameloss:

• Cardiac conduction effects: Ameloss has vagotonic effects on the sinoatrial and atrioventricular nodes and may cause bradycardia, heart block, or syncope, particularly in patients with underlying cardiac conduction abnormalities or those on other heart-rate-lowering drugs.
• Gastrointestinal bleeding risk: Due to increased gastric acid secretion, patients with a history of peptic ulcer disease or those taking NSAIDs concurrently are at increased risk of gastrointestinal bleeding; monitor for symptoms such as black or bloody stools.
• Bladder outflow obstruction: May cause or worsen urinary retention in susceptible patients.
• Seizures: Cholinesterase inhibitors are thought to have some potential to cause generalized convulsions; seizure activity may also be a manifestation of Alzheimer's disease itself.
• Anesthesia: Ameloss is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia; inform the anesthesiologist before any surgical procedure.
• Pulmonary conditions: Use with caution in patients with a history of asthma or obstructive pulmonary disease, as cholinergic effects may worsen these conditions.
• Weight loss: Regular monitoring of body weight is advisable, particularly at higher doses.

Take Ameloss exactly as prescribed by your physician; do not stop, skip doses, alter the dose, or share this medicine with others without medical advice, since abrupt discontinuation may worsen cognitive symptoms.

Overdose of Ameloss may cause a cholinergic crisis, with symptoms such as severe nausea, vomiting, salivation, sweating, slow heart rate, low blood pressure, difficulty breathing, muscle weakness, collapse, and convulsions, which can be life-threatening.

Suspected overdose is a medical emergency. Seek immediate medical attention or contact emergency services/poison control; do not attempt home treatment. Management in a hospital setting may include supportive care and administration of an antidote (such as atropine) by trained medical personnel.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Ameloss is primarily used in the elderly population, as Alzheimer's disease predominantly affects older adults; no specific dose adjustment based on age alone is required, but this population should be monitored closely for cardiac and gastrointestinal side effects.

Renal impairment

No dose adjustment is required (see Dosage and Administration).

Hepatic impairment

Use with caution; clearance may be reduced (see Dosage and Administration).

Pediatric patients

Safety and effectiveness have not been established in pediatric patients (see Pediatric Uses).

Treatment with Ameloss for Alzheimer's disease is typically long-term/chronic, as it addresses symptoms of an ongoing progressive condition rather than curing it. The physician should periodically reassess whether continued therapy provides clinical benefit, and treatment should not be stopped or changed without medical advice.

Anti-dementia agent; Cholinesterase inhibitor (Acetylcholinesterase inhibitor); Piperidine derivative.

Donepezil Hydrochloride reversibly and selectively inhibits acetylcholinesterase, the enzyme responsible for hydrolyzing acetylcholine in the central nervous system. This inhibition increases the availability of acetylcholine at cholinergic synapses, helping to compensate for the loss of cholinergic neurons that occurs in Alzheimer's disease and thereby improving cholinergic neurotransmission relevant to memory and cognition.

C

The safety and effectiveness of Ameloss have not been established in pediatric patients. It is not indicated or recommended for use in children or adolescents, and should only be used in adults with a physician-confirmed diagnosis requiring treatment.